GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Hspa5 | affects localization | EXP | | 6480464 | CTD | Lipopolysaccharides affects the localization of HSPA5 protein | PMID:17475668 | Hspa5 | decreases expression | EXP | | 6480464 | CTD | Lipopolysaccharides results in decreased expression of HSPA5 protein | PMID:21355878 | Hspa5 | increases expression | EXP | | 6480464 | CTD | Lipopolysaccharides results in increased expression of HSPA5 protein | PMID:28245985 | Hspa5 | multiple interactions | EXP | | 6480464 | CTD | 4-phenylbutyric acid inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; Vaticanol B inhibits the reaction [Lipopolysaccharides affects the localization of HSPA5 protein] | PMID:17475668 PMID:28245985 | Hspa5 | increases expression | ISO | Hspa5 (Rattus norvegicus) | 6480464 | CTD | Lipopolysaccharides results in increased expression of HSPA5 protein | PMID:33677747 | Hspa5 | increases expression | ISO | HSPA5 (Homo sapiens) | 6480464 | CTD | Lipopolysaccharides results in increased expression of HSPA5 protein | PMID:19675143 PMID:28245985 PMID:30918470 PMID:33677747 | Hspa5 | multiple interactions | ISO | Hspa5 (Rattus norvegicus) | 6480464 | CTD | 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; SREBF2 protein affects the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein] | PMID:28844859 PMID:33677747 | Hspa5 | multiple interactions | ISO | HSPA5 (Homo sapiens) | 6480464 | CTD | 3-methyladenine promotes the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; 4-phenylbutyric acid inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; [NAT10 protein affects the susceptibility to Lipopolysaccharides] which affects the expression of HSPA5 mRNA; [usnic acid co-treated with Lipopolysaccharides] results in decreased expression of HSPA5 mRNA; betadex inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; MIR590 mRNA inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein]; SREBF2 protein affects the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; UBE2I protein inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein] | PMID:22777745 PMID:24149798 PMID:28245985 PMID:30918470 PMID:33677747 PMID:35877022 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |